Get the Stockscreener App
4.20
2.19%
0.09
After Hours:
4.20
Xenetic Biosciences Inc stock is traded at $4.20, with a volume of 60,749.
It is up +2.19% in the last 24 hours and up +10.67% over the past month.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
See More
Previous Close:
$4.11
Open:
$4.13
24h Volume:
60,749
Relative Volume:
2.89
Market Cap:
$6.71M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.4533
EPS:
-2.89
Net Cash Flow:
$-4.11M
1W Performance:
+5.26%
1M Performance:
+10.67%
6M Performance:
+7.73%
1Y Performance:
+35.48%
1-Day Range:
$4.09
$4.47
1-Week Range:
$3.81
$4.47
52-Week Range:
$2.78
$5.20
Xenetic Biosciences Inc Stock (XBIO) Company Profile
Name
Xenetic Biosciences Inc
Sector
Industry
Phone
781-778-7720
Address
945 CONCORD ST., FRAMINGHAM, MA
Compare XBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIO
Xenetic Biosciences Inc
|
4.20 | 6.71M | 2.54M | -4.13M | -4.11M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-20 | Initiated | Maxim Group | Buy |
Xenetic Biosciences Inc Stock (XBIO) Latest News
HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - AccessWire
Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan
XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire
Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - AccessWire
Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan
Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle
Xenetic presents preclinical data on DNase platform technology - TipRanks
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Oil City Derrick
Xenetic's DNase I Breakthrough Boosts Cancer Immunotherapy Efficacy in Preclinical Study | XBIO Stock News - StockTitan
Xenetic Biosciences Extends Research Collaboration with The Scripps Research Institute - Defense World
Xenetic extends research collaboration with Scripps Research Institute - TipRanks
Xenetic Biosciences Expands Collaboration for Cancer Treatment - TipRanks
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - AccessWire
Xenetic Biosciences announces board member changes - Investing.com India
Xenetic Biosciences announces board member changes By Investing.com - Investing.com UK
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 460.0% - Defense World
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - AccessWire
SEC Form S-3 filed by Xenetic Biosciences Inc. - Quantisnow
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - AccessWire
Secondary Progressive Multiple Sclerosis Drug Market to Expand with Significant CAGR by 2034 |AB Science SA, Actelion Lt – IndiaPolitics.com - IndiaPolitics.com
Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 50.0% - Defense World
Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Significant Decline in Short Interest - Defense World
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Kansas City Star
Q3 2024 Earnings Estimate for Xenetic Biosciences Inc (NASDAQ:XBIO) Issued By HC Wainwright - Defense World
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024 - MSN
Xenetic Biosciences (NASDAQ:XBIOW) Stock Price Up 33.9% - Defense World
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates - MSN
Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World
Xenetic Biosciences Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line - Simply Wall St
Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Hits Estimates - Defense World
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Markets Insider
Xenetic Biosciences: Q2 Earnings Snapshot - CTPost
Xenetic Biosciences Inc Stock (XBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):